BioAge Labs (BIOA) Stock Price, News, Quotes-Moomoo

English
中文繁體
中文简体

Dark
Light

Open Account

Download

US Stock MarketDetailed Quotes

BIOA BioAge Labs

Watchlist

4.630
+0.260+5.95%

Close Feb 28 16:00 ET

4.640
+0.010+0.21%

Post 20:01 ET

165.98MMarket Cap-2.23P/E (TTM)

Full Hours

5D
Daily
Weekly
Monthly
1Q
1Y

Trade Overview

Unit: --

Capital Trend

IntradayDayWeekMonth

No Data

News

Bioage Labs Initiated at Market Perform by William Blair
Dow JonesFeb 28 07:14 ET · Ratings
Bioage Labs Analyst Ratings
BenzingaFeb 28 07:03 ET · Ratings
William Blair Initiates BioAge Labs(BIOA.US) With Hold Rating, Announces Target Price $10
Moomoo NewsFeb 27 16:32 ET · Ratings
BioAge Labs to Participate in TD Cowen's 45th Annual Health Care Conference
GlobeNewswireFeb 20 16:30 ET
Interest in AI-Powered MedTech is on the Rise: Key Stocks to Watch
Analysts NotebookFeb 13 06:50 ET
Citi Downgrades BioAge Labs(BIOA.US) to Hold Rating, Cuts Target Price to $7
Moomoo NewsJan 29 07:31 ET · Ratings

Comments

Teddy123

Feb 28 07:17

The Committee for Medicinal Products for Human Use (CHMP) reaffirms positive opinion for Lecanemab in early Alzheimer's disease in the EU

$BioAge Labs (BIOA.US)$ $
BioArctic's Alzheimer's Drug Clears Critical EU Regulatory Hurdle After Safety Evaluation

Teddy123

Feb 20 03:44

BioArctic's global license agreement with Bristol Myers Squibb for PyroGlutamate-amyloid-beta antibody program effective after antitrust clearance and closing

$BioAge Labs (BIOA.US)$
Alzheimer's Drug Deal: How BioArctic's $1.3B Bristol Myers Agreement Could Transform Treatment

Sean Parker

Feb 20 00:39

BioArctic's global license agreement with Bristol Myers Squibb for PyroGlutamate-amyloid-beta antibody program effective after antitrust clearance and closing

$BioAge Labs (BIOA.US)$
BioArctic AB announced the completion of its global license agreement with Bristol Myers Squibb after receiving U.S. Federal Trade Commission clearance. The agreement, initially announced on December 19, 2024, grants Bristol Myers Squibb worldwide development and commercialization rights for BAN1503 and BAN2803, part ...

Teddy123

Feb 18 03:56

Leqembi® sales reaches €200 million - first sales milestone achieved

$BioAge Labs (BIOA.US)$
Milestone Achievement: Alzheimer's Breakthrough Leqembi Reaches €200M Sales, Triggering Major Payout

Analysts Notebook

Feb 13 05:50

Columns Interest in AI-Powered MedTech is on the Rise: Key Stocks to Watch

The attention of AI Medteck stocks are rapidly increasing.
Pelosi's new holdings have doubled $Tempus AI (TEM.US)$ value in just a few weeks, and $Firefly Neuroscience (AIFF.US)$'s inclusion in NVIDIA's Connect program has also caused its stock price to soar.
In addition, DeepSeek's rapid rise has boosted the AI application sector, particularly in medicine/healthcare. Cathie Wood believes medical AI is undervalued, with untapped pot...